With its profound accumulation and continuous innovation in the field of biomedicine,InnoModels Biotechnology has successfully launched the iHuPDX platform. With its unique advantages, this platform has revolutionized individualized tumor research and treatment.
The core feature of iHuPDX platform is its xenotransplantation technology based on patients' individual tumor cells. Through the fine collection and processing of patient cancer tissue samples, the platform is able to transplant these cells into animals such as mice to form highly individualized transplanted tumors. The successful implementation of this technology allows researchers to conduct in-depth studies of tumor growth, development and drug response in an environment that is closer to the actual patient situation.
First, the iHuPDX platform is highly individualized. Since it is a disease model based on individual patient's tumor cells, it is able to better reflect the patient's tumor characteristics. The establishment of such individualized models not only contributes to a more comprehensive understanding of a patient's tumor biology, but also provides strong support for precision medicine. Through in-depth study of these models, doctors can more accurately determine a patient's condition and develop a more personalized treatment plan.

Second, the iHuPDX platform shows great potential in drug response prediction. Due to the highly individualized nature of the models, the platform can be used to test the response of different drugs to a specific patient's tumor. This feature provides strong support for the development of personalized treatment plans and helps doctors choose more effective drugs with fewer side effects for their patients. Meanwhile, through the prediction of drug response, potential drug resistance problems can also be detected in advance, providing an important reference for the adjustment of treatment programs.
In addition, the iHuPDX platform provides a new perspective for cancer research. By comparing the tumor heterogeneity between different patients, researchers can gain a deeper understanding of the diversity of cancer and reveal the mechanisms of its occurrence and development. This shift in perspective not only helps to promote the development of cancer research, but also provides an important theoretical basis for the development of individualized treatment strategies.
The iHuPDX platform also excels in model stability and growth rate. The platform uses primary cell inoculation technology to ensure homogenization of samples between batches through cell suspension modeling. This ensures a high degree of consistency in the growth rate and biological characteristics of samples from the same batch, laying a solid foundation for model stability. Meanwhile, the platform also realizes the early and uniform growth of transplanted tumors by optimizing the culture conditions and transplantation technology, which provides the best experimental window for drug efficacy experiments.
In summary, the iHuPDX platform of InnoModels Biotechnology provides strong support for individualized tumor research and treatment with its highly individualized disease model, accurate drug response prediction capability, and a new perspective on cancer research. With the continuous development and improvement of this platform, it is believed that it will bring benefits to more tumor patients in the future and promote the advancement of medical career.